R. Xinyu

560 total citations
9 papers, 229 citations indexed

About

R. Xinyu is a scholar working on Infectious Diseases, Computational Theory and Mathematics and Molecular Biology. According to data from OpenAlex, R. Xinyu has authored 9 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Computational Theory and Mathematics and 2 papers in Molecular Biology. Recurrent topics in R. Xinyu's work include SARS-CoV-2 and COVID-19 Research (6 papers), Computational Drug Discovery Methods (6 papers) and Peptidase Inhibition and Analysis (2 papers). R. Xinyu is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (6 papers), Computational Drug Discovery Methods (6 papers) and Peptidase Inhibition and Analysis (2 papers). R. Xinyu collaborates with scholars based in United States. R. Xinyu's co-authors include Wenshe Ray Liu, Shiqing Xu, Yuying Ma, Yugendar R. Alugubelli, Erol C. Vatansever, Kai S. Yang, Lauren R. Blankenship, Zhi Geng, Kaustav Khatua and Namir Shaabani and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and ACS Central Science.

In The Last Decade

R. Xinyu

9 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Xinyu United States	8	116	105	101	51	28	9	229
Yugendar R. Alugubelli United States	8	118 1.0×	106 1.0×	99 1.0×	50 1.0×	27 1.0×	13	227
Bin Tan United States	8	155 1.3×	136 1.3×	110 1.1×	97 1.9×	25 0.9×	13	310
Erol C. Vatansever United States	10	162 1.4×	147 1.4×	150 1.5×	83 1.6×	42 1.5×	12	329
Lauren R. Blankenship United States	8	71 0.6×	74 0.7×	80 0.8×	46 0.9×	22 0.8×	12	176
Jimmy Lu Canada	6	141 1.2×	125 1.2×	63 0.6×	45 0.9×	17 0.6×	8	204
Mackenzie E. Chapman United States	3	141 1.2×	131 1.2×	75 0.7×	55 1.1×	25 0.9×	4	264
Zhengnan Shen United States	8	101 0.9×	72 0.7×	117 1.2×	41 0.8×	47 1.7×	11	272
Lian Jacobs United States	4	148 1.3×	72 0.7×	69 0.7×	32 0.6×	16 0.6×	6	217
Pengjiao Hou China	6	149 1.3×	143 1.4×	160 1.6×	30 0.6×	36 1.3×	7	327
Henry Ji United States	9	101 0.9×	68 0.6×	75 0.7×	34 0.7×	49 1.8×	21	239

Countries citing papers authored by R. Xinyu

Since Specialization

Citations

This map shows the geographic impact of R. Xinyu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Xinyu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Xinyu more than expected).

Fields of papers citing papers by R. Xinyu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Xinyu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Xinyu. The network helps show where R. Xinyu may publish in the future.

Co-authorship network of co-authors of R. Xinyu

This figure shows the co-authorship network connecting the top 25 collaborators of R. Xinyu. A scholar is included among the top collaborators of R. Xinyu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Xinyu. R. Xinyu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Khatua, Kaustav, Yugendar R. Alugubelli, Kai S. Yang, et al.. (2024). Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors. Antiviral Research. 225. 105874–105874. 7 indexed citations

Alugubelli, Yugendar R., Kaustav Khatua, Long Sun, et al.. (2024). Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 67(8). 6495–6507. 32 indexed citations

Blankenship, Lauren R., Kai S. Yang, Yugendar R. Alugubelli, et al.. (2024). SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme. ACS Medicinal Chemistry Letters. 15(6). 950–957. 2 indexed citations

Geng, Zhi, Namir Shaabani, Kai S. Yang, et al.. (2023). A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 66(16). 11040–11055. 14 indexed citations

Alugubelli, Yugendar R., Zhi Geng, Kai S. Yang, et al.. (2022). A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. European Journal of Medicinal Chemistry. 240. 114596–114596. 33 indexed citations

Ma, Yuying, Kai S. Yang, Zhi Geng, et al.. (2022). A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. European Journal of Medicinal Chemistry. 240. 114570–114570. 28 indexed citations

Cao, Wenyue, Zhi Geng, Namir Shaabani, et al.. (2022). Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay. ACS Central Science. 8(2). 192–204. 38 indexed citations

Xinyu, R., Yugendar R. Alugubelli, Yuying Ma, et al.. (2021). MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L**. ChemMedChem. 17(1). e202100456–e202100456. 46 indexed citations

Xinyu, R., Longxia Xu, Shiqing Xu, et al.. (2021). Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain. Journal of Medicinal Chemistry. 64(15). 10997–11013. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact